Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2019.05.08
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response ...
PDF (181 KB)
2019.05.14
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 I ...
PDF (266 KB)
2019.05.14
FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo’s Pexidartinib for the Trea ...
PDF (259 KB)
2019.05.15
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and P ...
PDF (177 KB)
2019.05.31
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EG ...
PDF (158 KB)
2019.06.01
Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosyno ...
PDF (244 KB)
2019.06.02
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with N ...
PDF (193 KB)
2019.06.18
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...
PDF (153 KB)
2019.06.21
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Rela ...
PDF (206 KB)
2019.08.02
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...
PDF (368 KB)
Showing 1 - 10 of 35 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...